-
Mashup Score: 11Offline: It is time to take cancer more seriously - 6 day(s) ago
The Lancet has published two Commissions in 2024 addressing the commonest cancers among men and women: prostate cancer (led by Nicholas James) and breast cancer (led by Charlotte Coles). As we were preparing these Commissions for publication, we considered writing an editorial linking the two cancers. But we hesitated. Surely these conditions are distinguished by their differences, not their similarities. Breast cancer is preventable. No such possibilities exist for prostate cancer. As our Commission on Prostate Cancer concluded: “The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions.” Yet, observing their launches and listening to the debates they provoked suggests that these cancers have more in common than might be appreciated—synergies that have important implications for accelerating cancer prevention and control.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11Offline: It is time to take cancer more seriously - 6 day(s) ago
The Lancet has published two Commissions in 2024 addressing the commonest cancers among men and women: prostate cancer (led by Nicholas James) and breast cancer (led by Charlotte Coles). As we were preparing these Commissions for publication, we considered writing an editorial linking the two cancers. But we hesitated. Surely these conditions are distinguished by their differences, not their similarities. Breast cancer is preventable. No such possibilities exist for prostate cancer. As our Commission on Prostate Cancer concluded: “The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions.” Yet, observing their launches and listening to the debates they provoked suggests that these cancers have more in common than might be appreciated—synergies that have important implications for accelerating cancer prevention and control.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11Offline: It is time to take cancer more seriously - 6 day(s) ago
The Lancet has published two Commissions in 2024 addressing the commonest cancers among men and women: prostate cancer (led by Nicholas James) and breast cancer (led by Charlotte Coles). As we were preparing these Commissions for publication, we considered writing an editorial linking the two cancers. But we hesitated. Surely these conditions are distinguished by their differences, not their similarities. Breast cancer is preventable. No such possibilities exist for prostate cancer. As our Commission on Prostate Cancer concluded: “The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions.” Yet, observing their launches and listening to the debates they provoked suggests that these cancers have more in common than might be appreciated—synergies that have important implications for accelerating cancer prevention and control.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11Offline: It is time to take cancer more seriously - 6 day(s) ago
The Lancet has published two Commissions in 2024 addressing the commonest cancers among men and women: prostate cancer (led by Nicholas James) and breast cancer (led by Charlotte Coles). As we were preparing these Commissions for publication, we considered writing an editorial linking the two cancers. But we hesitated. Surely these conditions are distinguished by their differences, not their similarities. Breast cancer is preventable. No such possibilities exist for prostate cancer. As our Commission on Prostate Cancer concluded: “The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions.” Yet, observing their launches and listening to the debates they provoked suggests that these cancers have more in common than might be appreciated—synergies that have important implications for accelerating cancer prevention and control.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11Offline: It is time to take cancer more seriously - 6 day(s) ago
The Lancet has published two Commissions in 2024 addressing the commonest cancers among men and women: prostate cancer (led by Nicholas James) and breast cancer (led by Charlotte Coles). As we were preparing these Commissions for publication, we considered writing an editorial linking the two cancers. But we hesitated. Surely these conditions are distinguished by their differences, not their similarities. Breast cancer is preventable. No such possibilities exist for prostate cancer. As our Commission on Prostate Cancer concluded: “The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions.” Yet, observing their launches and listening to the debates they provoked suggests that these cancers have more in common than might be appreciated—synergies that have important implications for accelerating cancer prevention and control.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11Offline: It is time to take cancer more seriously - 6 day(s) ago
The Lancet has published two Commissions in 2024 addressing the commonest cancers among men and women: prostate cancer (led by Nicholas James) and breast cancer (led by Charlotte Coles). As we were preparing these Commissions for publication, we considered writing an editorial linking the two cancers. But we hesitated. Surely these conditions are distinguished by their differences, not their similarities. Breast cancer is preventable. No such possibilities exist for prostate cancer. As our Commission on Prostate Cancer concluded: “The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions.” Yet, observing their launches and listening to the debates they provoked suggests that these cancers have more in common than might be appreciated—synergies that have important implications for accelerating cancer prevention and control.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 2Randomised controlled trials evaluating artificial intelligence in clinical practice: a scoping review - 7 day(s) ago
This scoping review of randomised controlled trials on artificial intelligence (AI) in clinical practice reveals an expanding interest in AI across clinical specialties and locations. The USA and China are leading in the number of trials, with a focus on deep learning systems for medical imaging, particularly in gastroenterology and radiology. A majority of trials (70 [81%] of 86) report positive primary endpoints, primarily related to diagnostic yield or performance; however, the predominance of single-centre trials, little demographic reporting, and varying reports of operational efficiency raise concerns about the generalisability and practicality of these results.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 19
Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials.
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1418F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer - 14 day(s) ago
Anti–programmed death 1 (PD-1) inhibitors are the standard of care for advanced gastroesophageal cancer. Although recommendations and approval by regulatory agencies are often based on programmed death ligand 1 (PD-L1) expression, pathologic assessments of PD-L1 status have several limitations. Single-site biopsies do not adequately capture disease heterogeneity within individual tumor lesions or among several lesions within the same patient, the PD-L1 combined positive score is a dynamic biomarker subject to evolution throughout a patient’s disease course, and repeated biopsies are invasive and not always feasible. Methods: This was a prospective pilot study of the PD-L1–targeting radiotracer, 18F-BMS-986229, with PET imaging (PD-L1 PET) in patients with gastroesophageal cancer. Patients were administered the 18F-BMS-986229 radiotracer intravenously at a dose of 370 MBq over 1–2 min and underwent whole-body PET/CT imaging 60 min later. The primary objective of this study was to evalua
Source: jnm.snmjournals.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 10Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval - 24 day(s) ago
This study aims to determine whether cancer drugs granted accelerated approval from the US Food and Drug Administration ultimately demonstrate clinical benefit and to evaluate the basis of conversion to regular approval.
Source: jamanetwork.comCategories: General Medicine News, Oncologists2Tweet
Offline: It is time to take cancer more seriously - The Lancet https://t.co/LMYAlesbsW